The FDA has granted Breakthrough Therapy designation to sotatercept (Acceleron Pharma) for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization Group 1).
Combination therapy is appropriate for patients with typical pulmonary arterial hypertension who are categorized as low and intermediate risk at baseline.
Obesity may be associated with a greater risk for pulmonary hypertension.
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse® (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF).
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
No causal association between elevated red cell distribution width and pulmonary arterial hypertension was established.
Bellerophon Therapeutics announced positive topline results from cohort 2 of an ongoing phase 2/3 iNO-PF study of INOpulse delivery system for the treatment of PH-ILD.
In patients with abnormal vital signs presenting to the emergency department who are suspected of having a pulmonary embolism, a negative focused cardiac ultrasound examination may be associated with reduced odds of a pulmonary embolism diagnosis.